News Medicare obesity drug pilot extended after insurer pushback Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.
News Obesity biotech Kailera's record-breaking IPO When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.
News 23andMe study explains variable results with obesity drugs Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Patients Reframing obesity beyond stigma and simplicity Deep Dive editor Eloise McLennan reports on Novo Nordisk's inaugural Weight Talks Summit in London.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
News Obesity-focused biotech Kailera joins IPO queue in US Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
News FDA greenlights Regeneron drug for rare bone disease Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
